References
  1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
  2. Frederix I, Dendale P, Schmid JP. Who needs secondary prevention?. Eur J Prev Cardiol. 2017;24(3_suppl):8-13.
  3. Elmariah S, Rao SV, Grines CL, Garratt KN, Caputo RP, et al. How can SCAI and industry partners increase adherence and educate interventionalists on optimal medical therapy?. Catheter Cardiovasc Interv. 2019;93(2):305-308.
  4. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005375.
  5. Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis. Eur J Prev Cardiol. 2017;24(9):962-970.
  6. Gibbons RJ, Miller TD. Optimal Medical Therapy for Known Coronary Artery Disease: A Review. JAMA Cardiol. 2017;2(9):1030-1035.
  7. Chen ST, Huang ST, Shau WY, et al. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19(1):62.
  8. Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. J Am Coll Cardiol. 2015;66(2):184-92.
  9. Rodriguez F, Maron DJ, Knowles JW, et al. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019;4(3):206-213.
  10. Sabatè E. Adherence to long-term therapies: Evidence for action: World Health Organization. Towards the Solution. 2003. p.27-38.
  11. Bradley CK, Wang TY, Li S, et al. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019;8(7):e011765.
  12. Samaras K, Makkar SR, Crawford JD, et al. Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. J Am Coll Cardiol. 2019;74(21):2554-2568.
  13. Abughosh SM, Vadhariya A, Johnson ML, et al. Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. J Manag Care Spec Pharm. 2019;25(10):1053-1062.
  14. Ahmed ST, Akeroyd JM, Mahtta D, et al. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020;9(22):e017915.
  15. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291.
  16. Muñoz D, Uzoije P, Reynolds C, et al. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med. 2019;381(12):1114-1123.
  17. Singh K, Crossan C, Laba TL, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol. 2018;262:71-78.
  18. Jowett S, Barton P, Roalfe A, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One. 2017;12(9):e0182625.
  19. Franczyk B, Gluba-Brzózka A, Jurkiewicz L, et al. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Expert Opin Pharmacother. 2018;19(17):1857-1865.
  20. Sukonthasarn A, Chia YC, Wang JG, et al. The feasibility of polypill for cardiovascular disease prevention in Asian Population. J Clin Hypertens (Greenwich). 2021;23(3):545-555.
  21. López-Jaramillo P, González-Gómez S, Zarate-Bernal D, et al. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries. Ther Adv Cardiovasc Dis. 2018;12(6):169-174.
  22. Ferket BS, Hunink MG, Khanji M, et al. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart. 2017;103(7):483-491.
  23. Cordero A, Rodriguez Padial L, Batalla A, et al. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study. Cardiovasc Ther. 2017;35(2).
  24. Khunti K, Danese MD, Kutikova L, et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open. 2018;1(8):e185554.
  25. Ramsaran E, Preusse P, Sundaresan D, et al. Adherence to Blood Cholesterol Treatment Guidelines Among Physicians Managing Patients With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019;124(2):169-175.
  26. Reston JT, Buelt A, Donahue MP, et al. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. Ann Intern Med. 2020;173(10):806-812.
  27. Ahmed ST, Mahtta D, Rehman H, et al. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system. Am Heart J. 2020;221:9-18.
  28. Rehman H, Ahmed ST, Akeroyd J, et al. Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). Am J Cardiol. 2019;124(8):1165-1170.
  29. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283-91.
  30. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991-1001.
  31. Khan AA, Khalid MF, Ayub MT, et al. Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A Comprehensive Meta-analysis. Curr Probl Cardiol. 2021;46(3):100695.
  32. Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence and Long-Term Predictive Validity of Blood Pressure Control. Medical Care 1986.
  33. Morisky DE, Malotte CK, Choi P, et al. A Patient Education Program to Improve Rate with Antituberculosis Drug Regimens. Health Education Quarterly 1990; 17:253-268
  34. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: Final response. J Clin Epidemio 2011; 64(3):262-263.